Non-Small Cell Lung Cancer

New Drug: Selpercatinib in RET-Fusion Positive NSCLC

2022-11-26

  • Study

    Open-label phase 1–2 trial
    Previously platinum-based chemotherapy
    Advanced or metastatic RET fusion positive NSCLC pts who had been treated with platinum (phase I: 49 pts) and who were untreated (phase II: 56 pts)
    Selpercatinib 160 mg twice daily

  • Efficacy

    ORR: 64% (CR:2%, PR:62%, SD:29%)
    DOR: 17.5 months
    mPFS: 16.5 months

  • Safety

    Any grade AEs: 91%, dry mouth:36%, diarrhea:25%, AST elevation:30%
    Any grade ≥3 AEs: Hypertension:14%, ALT elevation:13%, hyponatremia: 6%, lymphopenia:6%


    • N Engl J Med 2020; 383:813-824

    Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    http://doi.org/10.1056/NEJMoa2005653

    Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022